News | September 08, 2025
Strides partners with Kenox to expand nasal spray portfolio for US market
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Subscribe To Our Newsletter & Stay Updated
